Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands.
The Ras/mitogen-activated protein kinase (MAPK) pathway is considered to be a positive regulator of tumor initiation, progression, and maintenance. This study reports an opposite finding: we have found strong evidence that the MAPK pathway is inhibited in a subset of adenoid cystic carcinomas (ACCs) of the salivary glands. ACC tumors consistently overexpress the receptor tyrosine kinase (RTK) c-Kit, which has been considered a therapeutic target. We performed mutational analysis of the c-Kit gene (KIT in 17 cases of ACC and found that 2 cases of ACC had distinct missense mutations in KIT at both the genomic DNA and messenger RNA levels. These mutations caused G664R and R796G amino acid substitutions in the kinase domains. Surprisingly, the mutations were functionally inactive in cultured cells. We observed a significant reduction of MAPK (ERK1/2) activity in tumor cells, as assessed by immunohistochemistry. We performed further mutational analysis of the downstream effectors in the c-Kit pathway in the genes HRAS, KRAS, NRAS, BRAF, PIK3CA, and PTEN. This analysis revealed that two ACC tumors without KIT mutations had missense mutations in either KRAS or BRAF, causing S17N K-Ras and V590I B-Raf mutants, respectively. Our functional analysis showed that proteins with these mutations were also inactive in cultured cells. This is the first time that MAPK activity from the RTK signaling has been shown to be inhibited by gene mutations during tumor development. Because ACC seems to proliferate despite inactivation of the c-Kit signaling pathway, we suggest that selective inhibition of c-Kit is probably not a suitable treatment strategy for ACC.
Tetsu
Osamu
O
Head and Neck Cancer Research Laboratory, Department of Otolaryngology-Head and Neck Surgery, School of Medicine, University of California, San Francisco, San Francisco, CA 94143-1330, USA. otetsu@ohns.ucsf.edu
Phuchareon
Janyaporn
J
Chou
Annie
A
Cox
Darren P
DP
Eisele
David W
DW
Jordan
Richard C K
RC
D000328:Adult; D000368:Aged; D003528:Carcinoma, Adenoid Cystic / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D016022:Case-Control Studies; D049109:Cell Proliferation; D004252:DNA Mutational Analysis; D018450:Disease Progression; D005260:Female; D006801:Humans; D020935:MAP Kinase Signaling System / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense / Q000502:physiology; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics* / Q000378:metabolism; D012468:Salivary Gland Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D014407:Tumor Cells, Cultured
D019009:Proto-Oncogene Proteins c-kit
Cell. 1993 Jul 30;74(2):395-404
8343963
Mol Cell Biol. 1988 Jun;8(6):2472-8
3043178
J Biol Chem. 1997 Apr 11;272(15):10248-53
9092574
Leukemia. 2005 Feb;19(2):310-2
15538400
Blood. 2002 Mar 1;99(5):1741-4
11861291
Anticancer Drugs. 2005 Aug;16(7):719-26
16027519
Nat Genet. 1998 Aug;19(4):323-4
9697690
Lab Invest. 2007 Apr;87(4):365-71
17259998
Cell. 2004 Mar 19;116(6):855-67
15035987
Cell. 1990 Oct 5;63(1):203-11
2208279
Curr Opin Genet Dev. 2004 Feb;14(1):37-42
15108803
Science. 1998 Jan 23;279(5350):577-80
9438854
J Biol Chem. 2003 Feb 14;278(7):4572-81
12458225
Am J Med Genet A. 2003 Oct 1;122A(2):125-32
12955764
Nat Genet. 2000 Feb;24(2):157-62
10655061
Trends Genet. 2000 Aug;16(8):368
10904266
Nature. 1986 Apr 3-9;320(6061):415-21
3007997
Mod Pathol. 2003 Dec;16(12):1224-31
14681323
J Mol Graph Model. 2004 Oct;23(2):139-52
15363456
J Clin Oncol. 2005 Sep 1;23(25):6271-3; author reply 6273-4
16135502
Genes Dev. 2000 Feb 1;14(3):301-12
10673502
EMBO J. 1987 Nov;6(11):3341-51
2448137
Am J Med Genet. 1998 Jan 6;75(1):101-3
9450866
Nature. 1988 Sep 1;335(6185):88-9
2457811
Cold Spring Harb Symp Quant Biol. 2005;70:461-7
16869784
J Clin Oncol. 2006 Jun 10;24(17):2673-8
16763282
Am J Surg. 1974 Oct;128(4):512-20
4371368
Nucleic Acids Res. 1988 Aug 25;16(16):7773-82
3047672
Cancer. 2009 Jan 1;115(1):75-83
18980290
Nat Rev Mol Cell Biol. 2008 Jul;9(7):517-31
18568040
Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8696-9
1717985
Science. 2003 Jan 31;299(5607):708-10
12522257
Hum Mol Genet. 2008 Feb 1;17(3):419-30
17981815
Science. 2004 Apr 23;304(5670):554
15016963
Head Neck. 2004 Sep;26(9):829-31
15350030
Nature. 2002 Jun 27;417(6892):949-54
12068308
Oncogene. 1999 Sep 30;18(40):5546-53
10523831
Nature. 1999 Apr 1;398(6726):422-6
10201372
Cell. 1988 May 20;53(4):549-54
2453289
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):988-94
17234357
Nat Rev Cancer. 2006 Aug;6(8):593-602
16862190
Mod Pathol. 1999 Oct;12(10):956-60
10530560
J Clin Oncol. 2005 Jan 20;23(3):585-90
15659505
Nat Genet. 1997 Apr;15(4):356-62
9090379
Blood. 1996 Aug 15;88(4):1225-33
8695840
Cell. 1988 Oct 7;55(1):185-92
2458842
Eur J Cancer. 2002 Sep;38 Suppl 5:S52-9
12528773
PLoS One. 2009 Jun 25;4(6):e6040
19557180